– USA, PA – OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, today announced the appointment of Carrie Eglinton Manner to its Board of Directors as President and CEO, effective June 4, 2022, to succeed Dr. interim CEO Nancy Gagliano, who will remain on the Board.
“Carrie has a proven track record of transformative leadership, disciplined operational execution, and driving innovation at two industry-leading healthcare companies,” said Board Chairman, Mike Celano. “Importantly, Carrie is a results-oriented executive who brings first-hand strategic insights into the testing industry and services businesses. The Board is confident that Carrie’s experience and skill set make her ideally suited to lead OraSure as we continue to scale up manufacturing for InteliSwab and drive growth across all of our platforms.”
About Carrie Eglinton Manner
Ms. Eglinton Manner brings more than 25 years of healthcare leadership and transformation expertise to OraSure. She is currently Senior Vice President, Advanced & General Diagnostics Clinical Solutions, at Quest Diagnostics. Under her leadership, Quest’s Advanced Diagnostics, a portfolio with over $2 billion in revenue, accelerated its growth rate with strong profitability. She has responsibility for bringing innovative diagnostic solutions to market in the areas of women’s health, neurology, oncology, cardiovascular, metabolic, endocrinology, infectious disease, and immunology testing services, as well as drug monitoring and toxicology.
Additionally, she leads Quest’s pharmaceutical services, AmeriPath/Dermpath, and international businesses. Ms. Eglinton Manner led Quest’s molecular genetics team in pioneering next-generation sequencing innovation which reduced cost and increased access for patients to precision health insights.
Before Quest Diagnostics, Ms. Eglinton Manner served for 20 years in a variety of leadership roles of increasing responsibility including multiple, distinct business units with global engineering and manufacturing responsibilities at GE Healthcare, a division of General Electric. A champion for inclusion and diversity, Ms. Eglinton Manner served as co-chair for Quest’s African American Employee Business Network, and before that, GE’s Women’s Network.
“I am thrilled to be joining OraSure at such a pivotal point in the Company’s growth story. Delivering insights to patients and driving access to testing are increasingly critical market needs for which OraSure is uniquely positioned to capitalize,” said Ms. Eglinton Manner. “Furthermore, we believe there are multiple opportunities to expand recent operational improvements, increase market reach and enhance efficiency across the company. I look forward to working closely with the Board and management to build upon the Company’s foundation, improve profitability and enhance shareholder value.”
About Carrie Eglinton Manner
Carrie Eglinton Manner currently serves as Quest Diagnostics’ Senior Vice President of Advanced & General Diagnostics Clinical Solutions. This position expanded on her previous role at SVP, Advanced Diagnostics, in which she served from January 2017 to March 2022, and in which she was responsible for more than $2 billion in revenue. Before joining Quest, she served for over two decades at GE Healthcare, a division of General Electric, including serving as the President and CEO of Detection and Guidance Solutions, President and CEO of Surgery / Orthopedic Equipment Company (OEC), President and CEO of Clarient Diagnostic Services, and President & CEO of Maternal-Infant Care / OHMEDA Medical, Inc. Ms. Eglinton Manner holds a Bachelor of Science in Mechanical Engineering from the University of Notre Dame.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities, and direct to consumers.
For more information: https://www.orasure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
